SG11201804225PA - Inhibitors of influenza virus replication, application methods and uses thereof - Google Patents

Inhibitors of influenza virus replication, application methods and uses thereof

Info

Publication number
SG11201804225PA
SG11201804225PA SG11201804225PA SG11201804225PA SG11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA
Authority
SG
Singapore
Prior art keywords
guangdong
international
dongyangguang
dongguan
zhen
Prior art date
Application number
SG11201804225PA
Inventor
Yingjun Zhang
Qingyun Ren
Changhua Tang
Xiaohong Lin
Junjun Yin
Kai Yi
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of SG11201804225PA publication Critical patent/SG11201804225PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date ..... ..sr.1 15 June 2017(15.06.2017) WIPO I PCT ID Hit (10) 1111111111111111111 WO International Ell 2017/097234 Publication 11111111111111111111111111111RIIIIIIIIIIIIIII Al Number (51) International Patent Classification: Dongyangguang Hi-tech Park, Zhen An Road No. 368, CO7D 471/04 (2006.01) A61K 31/522 (2006.01) Shang Sha, Chang An Town, Dongguan, Guangdong CO7D 519/00 (2006.01) A61K 31/519 (2006.01) 523871 (CN). A61K 31/52 (2006.01) A61K 31/517 (2006.01) A61K 31/437 (2006.01) A61K 31/5377 (2006.01) (74) Agent: TSINGYIHUA INTELLECTUAL PROPERTY A61K 31/506 (2006.01) A61P 31/16 (2006.01) LLC; Room 301 Trade Building, Zhaolanyuan, Tsinghua University, Qinghuayuan,Haidian District, Beijing 100084 (21) International Application Number: (CN). PCT/CN2016/109079 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 8 December 2016 (08.12.2016) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 201510908329.2 9 December 2015 (09.12.2015) CN NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: SUNSHINE LAKE PHARMA CO., LTD. RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, [CN/CN]; Northern Industrial Area, Songshan Lake, Dong- TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, guan, Guangdong 523000 (CN). ZA, ZM, ZW. (72) Inventors . ZHANG, Yingjun; Dongyangguang Hi-tech (84) Designated States (unless otherwise indicated, for every kind of regional available): ARIPO (BW, GH, Park, Zhen An Road No. 368, Shang Sha, Chang An protection Town, Dongguan, Guangdong 523871 REN, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (CN). Qingy- Dongyangguang Hi-tech Park, Zhen An Road No. 368, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, un; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Shang Sha, Chang An Town, Dongguan, Guangdong DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 523871 (CN). TANG, Changhua; Dongyangguang Hi- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, tech Park, Zhen An Road No. 368, Shang Sha, Chang An SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Town, Dongguan, Guangdong 523871 (CN). LIN, Xiao- hong; Dongyangguang HiPark, Zhen An Road No. GW, KM, ML, MR, NE, SN, TD, TG). -tech 368, Shang Sha, Chang An Town, Dongguan, Guangdong Published: 523871 (CN). YIN, Junjun; Dongyangguang Hi-tech with international search report (Art 21(3)) Park, Zhen An Road No. 368, Shang Sha, Chang An Town, Dongguan, Guangdong 523871 (CN). YI, Kai; 1-1 .4t i t M ei t--- cr\ O N 1-1 0 (54) Title: INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF ei : The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods 0 (57) thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
SG11201804225PA 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof SG11201804225PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510908329 2015-12-09
PCT/CN2016/109079 WO2017097234A1 (en) 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof

Publications (1)

Publication Number Publication Date
SG11201804225PA true SG11201804225PA (en) 2018-06-28

Family

ID=59012608

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804225PA SG11201804225PA (en) 2015-12-09 2016-12-08 Inhibitors of influenza virus replication, application methods and uses thereof

Country Status (11)

Country Link
US (2) US10717732B2 (en)
EP (1) EP3362451B1 (en)
JP (1) JP6952695B2 (en)
KR (1) KR20180088466A (en)
CN (2) CN109748915B (en)
AU (1) AU2016368317B2 (en)
CA (1) CA3005921A1 (en)
HK (1) HK1254668A1 (en)
RU (1) RU2737190C2 (en)
SG (1) SG11201804225PA (en)
WO (1) WO2017097234A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10717732B2 (en) * 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017198122A1 (en) * 2016-05-19 2017-11-23 四川大学 Anti-influenza small molecule compound and preparation method and use thereof
CN107759571B (en) 2016-08-16 2021-03-02 广东东阳光药业有限公司 Inhibitors of influenza virus replication and methods of use and uses thereof
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
EP3502112A4 (en) * 2016-09-05 2019-06-26 Guangdong Raynovent Biotech Co., Ltd. Anti-influenza virus pyrimidine derivative
CN108218873B (en) 2016-12-15 2020-07-07 广东东阳光药业有限公司 Inhibitors of influenza virus replication and uses thereof
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US11014941B2 (en) * 2017-04-24 2021-05-25 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
CN109384783A (en) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 Novel heterocyclic compounds and its medical usage as resisiting influenza virus inhibitor
BR112020016064A2 (en) * 2018-02-08 2020-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. HETEROARILLA COMPOUNDS, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND ITS THERAPEUTIC USE
RU2769050C1 (en) * 2018-03-05 2022-03-28 Гуандун Рэйновент Байотек Ко., Лтд. Crystalline form and salt form of a pyridoimidazole compound and a corresponding method of producing
CN110590768B (en) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents
CN110967239B (en) * 2020-01-02 2022-05-10 国家地质实验测试中心 Method for dissolving and oxidizing metallic chromium
CN117362318A (en) * 2020-07-10 2024-01-09 西藏海思科制药有限公司 PB2 inhibitor and preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011327A (en) * 2004-03-30 2006-12-15 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases.
RS55341B1 (en) 2009-06-17 2017-03-31 Vertex Pharma Inhibitors of influenza viruses replication
CN103562205A (en) 2010-12-16 2014-02-05 沃泰克斯药物股份有限公司 Inhibitors of influenza viruses replication
RU2013132681A (en) * 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед INFLUENZA VIRUS REPLICATION INHIBITORS
KR20130128436A (en) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of influenza viruses replication
CA2839937C (en) * 2011-07-05 2020-11-03 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
RU2685730C1 (en) 2013-11-13 2019-04-23 Вертекс Фармасьютикалз Инкорпорейтед Formulations of azaindole compounds
CA2930297C (en) * 2013-11-13 2022-04-05 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
PL3068776T3 (en) * 2013-11-13 2019-10-31 Vertex Pharma Inhibitors of influenza viruses replication
EA201790266A1 (en) 2014-08-08 2017-06-30 Янссен Сайенсиз Айрлэнд Юси INDOLS FOR USE IN INFECTIONS CAUSED BY THE FLU VIRUS
LT3191489T (en) 2014-09-08 2021-01-25 Janssen Sciences Ireland Unlimited Company Pyrrolopyrimidines for use in influenza virus infection
US10717732B2 (en) * 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza

Also Published As

Publication number Publication date
CN109748915B (en) 2021-03-26
AU2016368317B2 (en) 2019-05-23
AU2016368317A1 (en) 2018-06-07
US10717732B2 (en) 2020-07-21
WO2017097234A1 (en) 2017-06-15
KR20180088466A (en) 2018-08-03
EP3362451B1 (en) 2023-04-12
RU2018124993A3 (en) 2020-02-05
RU2737190C2 (en) 2020-11-25
EP3362451A1 (en) 2018-08-22
CN106854205A (en) 2017-06-16
CA3005921A1 (en) 2017-06-15
CN106854205B (en) 2019-07-09
HK1254668A1 (en) 2019-07-26
CN109748915A (en) 2019-05-14
US20200299294A1 (en) 2020-09-24
US11225477B2 (en) 2022-01-18
RU2018124993A (en) 2020-01-14
JP6952695B2 (en) 2021-10-20
JP2018536681A (en) 2018-12-13
EP3362451A4 (en) 2019-07-03
US20180346463A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
SG11201804225PA (en) Inhibitors of influenza virus replication, application methods and uses thereof
SG11201809874SA (en) Systems and methods for locating a wireless device
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805645QA (en) Lsd1 inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201907023UA (en) Method of reducing neutropenia
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201809024UA (en) Cancer immunotherapy by immune activation or immune modulation via globo series antigens
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201806284TA (en) Low pressure separator having an internal divider and uses therefor
SG11201805898RA (en) Liquid composition comprising a multistage polymer, its method of preparation and its use
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805001UA (en) Method of treating influenza a
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201901457TA (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201805204WA (en) Nicotine particle capsule
SG11201900408RA (en) Topical formulation for promoting wound healing
SG11201804440XA (en) Chemical reprogramming of human glial cells into neurons with small molecule cocktail
SG11201901477PA (en) Compound for use in the treatment of neurogenic orthostatic hypotension
SG11201903145TA (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone